Predictors of the community pharmacy white-coat effect in treated hypertensive patients. The MEPAFAR study

Objective : To determine whether age, gender, body mass index (BMI), community pharmacy blood pressure (CPBP), daytime ambulatory BP (ABP) variability, treatment compliance, number of anti-hypertensive drugs and smoking status are factors associated with the community pharmacy white-coat effect (CPW...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	International journal of clinical pharmacy 2011-06, Vol.33 (3), p.582-589, Article 582
Hauptverfasser:	Sabater-Hernández, Daniel, Sánchez-Villegas, Pablo, García-Corpas, José P., Amariles, Pedro, Sendra-Lillo, José, Faus, María J.
Format:	Artikel
Sprache:	eng
Schlagworte:	Aged Antihypertensive Agents - therapeutic use Blood pressure Blood Pressure Determination - methods Blood Pressure Determination - psychology Blood Pressure Monitoring, Ambulatory - methods Blood Pressure Monitoring, Ambulatory - psychology Community Pharmacy Services Cross-Sectional Studies Drug stores Female Humans Hypertension Hypertension - diagnosis Hypertension - psychology Hypertension - therapy Internal Medicine Male Medical tests Medicine Medicine & Public Health Middle Aged Pharmacy Predictive Value of Tests Professional-Patient Relations Research Article
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Objective : To determine whether age, gender, body mass index (BMI), community pharmacy blood pressure (CPBP), daytime ambulatory BP (ABP) variability, treatment compliance, number of anti-hypertensive drugs and smoking status are factors associated with the community pharmacy white-coat effect (CPWCE) in treated hypertensive patients. Setting : Eight community pharmacies in Gran Canaria, Spain. Method : A cross-sectional study was carried out from June 2008 to June 2009. The study included treated hypertensive patients older than 18 years. Patients were excluded if: systolic BP (SBP)/diastolic BP (DBP) ≥200/110 mmHg, not-recommended or unable to perform home BP measurements, changes in anti-hypertensive treatment
ISSN:	2210-7703 2210-7711 2210-7711
DOI:	10.1007/s11096-011-9514-1